Startups
The PolyPeptide Group is a world leader in the industrial/commercial-scale manufacture of proprietary and generic GMP and non-GMP peptides. With 6 GMP sites and over 20 approvals, the PolyPeptide Group has the experience and infrastructure to support your project from development to commercialization.
Overview
Location
Sweden, Malmo
Employees
501-1000
Founded date
1996
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 31, 2026 | Samsung Biologics publishes prospectus for PolyPeptide public tender offer | Direct subsidiary Samsung Peptide AG acting as formal offeror of the public tender offer Publication of offer prospectus follows pre-announcement on July 20, 2026 Largest individual shareholder committed to tender all of its PolyPeptide sha... |
| Aug 28, 2026 | Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion | INCHEON, South Korea, Aug. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, lo... |
| Aug 11, 2026 | Peptide Synthesis Market Trends: Drug Development and Biopharmaceutical Innovation Driving Growth | The peptide synthesis market is witnessing strong growth as peptides gain increasing importance in pharmaceutical research, therapeutic development, diagnostics, and biotechnology. Peptide synthesis enables the production of customized pept... |
| Jul 23, 2026 | Samsung Biologics Reports Second Quarter 2026 Financial Results | Recorded Q2'26 revenue of KRW 1,321 billion and operating profit of KRW 586 billion Delivered stable business performance through continued disciplined execution Expanded global presence while advancing innovation and future growth ini... |
| Jul 20, 2026 | Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India | Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 ... |
| Jul 20, 2026 | Samsung Biologics makes $1.8 billion all-cash offer for Switzerland’s PolyPeptide Group | Samsung Biologics has made a 1.46 billion Swiss francs ($1.8 billion) bid for PolyPeptide Group. With the acquisition, the company will expand its pipeline into peptide therapeutics to tap into the booming weight-loss drug market. South Kor... |
| Aug 18, 2025 | The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB | The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB Mon, Aug 18, 2025 11:00 CET Report this content Ahead of the annual general meeting on 21 August 2025 in EQL Pharma AB, the Nomination Committee has present... |
| Jun 5, 2025 | Peptide Aggregation in Manufacturing: Mechanisms, Challenges and Case Studies, Upcoming Webinar Hosted by Xtalks | www.polypeptide.com In this free webinar, understand the mechanisms and types of peptide aggregation during manufacturing. Attendees will learn how to detect and characterize aggregates using orthogonal analytical tools (SEC, DLS, FTIR, TEM... |
| Apr 18, 2024 | Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group | Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group Thu, Apr 18, 2024 09:41 CET Report this content Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the ... |
Show more
Reviews 0
FAQ about PolyPeptide Group
When was PolyPeptide Group founded?
PolyPeptide Group was founded in 1996.
What has the press written about PolyPeptide Group?
Parsers VC has collected 15 articles mentioning PolyPeptide Group, among them “Samsung Biologics publishes prospectus for PolyPeptide public tender offer” (Aug 31, 2026) and “Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion” (Aug 28, 2026).
Is PolyPeptide Group still active?
Yes, PolyPeptide Group is active; its latest activity on Parsers VC dates from Oct 21, 2026.